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Objectives:ThePRISON-IV trial showed inferior outcome inpatientswith chronic total
occlusions (CTOs) treated with the ultrathin-struts (60 μm for stent diameter ≤3mm,
81μm >3mm) hybrid-sirolimus eluting stents (SES) compared with everolimus eluting
stents (EES, 81 μm). The aim of this study is to investigate if the use of smaller stents
(≤3mm) was responsible for the inferior outcome reported in the trial.
Methods: In the PRISON-IV trial 330 patients with CTO lesionwere randomized 1:1 to
receive either hybrid-SES or EES. The hybrid-SES failed to reach the non-inferiority
primary endpoint of in-segment late lumen loss (LLL) at 9-month angiographic follow-
up. In this sub-analysis, we divided the population according to the different size of
stents implanted in those receiving only stents with diameter ≤3mm (Group-A, 178
patients), only stents >3mm (Group-B, 59 patients), and those receiving stents of both
sizes (Group-C, 93 patients).
Results: Baseline and procedural characteristics were comparable in the three groups.
At angiographic follow-up, most of the adverse outcomes occurred in Group A, with
higher incidence of binary restenosis in the Hybrid-SES versus EES (10.3% vs 1.3%,
P = 0.03) and augmented in-stent diameter stenosis (26.04 ± 18.59% vs 21.24 ± 12.84,
P = 0.06). Similarly, optical coherence tomography (OCT), which was performed in 60
patients at follow-up, documented a mild trend toward lower values of minimum in
stent area in Hybrid-SES arm of Group A (4.4 ± 1.02mm2 vs 5.0 ± 1.28mm2,
respectively, P = 0.16).
Conclusions: The present analysis suggests that the inferior performance of the ultra-
thin hybrid-SES in CTO-PCI is particularly pronounced when smaller stent (≤3mm
diameter) are adopted, if compared with EES.
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1 | INTRODUCTION
Procedural success rates in percutaneous treatment of coronary
chronic total occlusions (CTOs) have certainly improved in the last
years,1,2 with continuous benefits deriving from developments in
materials, devices, and techniques. The clinical advantages of a full
coronary revascularization by means of CTO recanalization, as shown
in some reports, may lead to improved long-term survival in patients
presenting with both stable coronary artery disease (CAD) and acute
coronary syndrome (ACS).3–5 In addition, the long-term incidence of
cardiac adverse events resulted higher in this population than in
patients presentingwith non-CTO lesions.6–8On the other hand, CTOs
often present adverse plaque characteristics (eg, large calcium deposit,
superior lesion length, diffuse disease upstream, and downstream the
CTO lesion itself) challenging the performance of currently available
devices, even in the era of second-generation drug eluting stents
(DES). Moreover, unconventional approaches (including all sub-intimal
techniques) are commonly adopted to create a functional but not
physiological lumen to the distal vessel, thus creating an additionally
unfavorable premise for long-term clinical success.9 In these settings,
all DES features (ranging from strut thickness and composition to the
polymer and drug eluted) are involved in the procedural and clinical
success, as already demonstrated in the past for regular percutaneous
coronary intervention (PCI).10–13 In the PRISON IV randomized
multicentre trial, successfully reanalysed CTO lesions were randomly
allocated in a 1:1 fashion to stent implantation with Orsiro, a hybrid
ultrathin-strut sirolimus-eluting stent (SES, Biotronik, Berlin, Germany)
or Xience, a thin-strut (81 μm) everolimus-eluting stents (EES, Abbott
Vascular, Santa Clara, CA).14 The SES study device did not meet the
primary non-inferiority endpoint of in-segment late lumen loss (LLL)
estimated by Quantitative Coronary Analysis (QCA) at 8 month of
angiographic follow-up,mainly because of an increased rate of focal in-
stent restenosis in the SES group. The aim of the present analysis is to
investigate the role of the “real” ultrathin-struts SES (Orsiro with
diameter ≤3mm) in the less favorable angiographic outcome described
for this device in the PRISON IV trial.
2 | METHODS
This is a sub-analysis from the PRISON IV multicentre trial, whose
design, major inclusion and exclusion criteria, endpoints, definitions,
and results have been previously described in detail
(NCT01516723).2,14 Briefly, after successful recanalization of native
total or chronic total coronary occlusions, 330 patients were
randomized in a 1:1 fashion to receive either a hybrid Orsiro SES or
the Xience Prime/Xpedition EES. Of note, the SES consists of a cobalt-
chromium platform covered with a biodegradable polymer, made of
ultrathin 60 μm struts for stent diameters ≤3mm and 80 μm struts for
diameter >3mm, as indicated by the manufacturers. On the other
hand, the EES with durable polymer presents a cobalt-chromium
platform with a strut thickness of 81 μm. Procedural and technical
choices were left to the operator's discretion, and included both
femoral and radial approaches as well as antegrade and retrograde
techniques. All patients received dual antiplatelet therapy prior to the
procedure with the indication to maintain it for at least 12 months.
Clinical follow-up was scheduled at 1, 6, 9, and 12 months.
Angiographic follow-up was mandatory at 9 months.
In the present analysis, we investigated the hypothesis that the
thinner struts platform of the SESwith diameter ≤3mmmay have been
responsible for the inferior angiographic outcome observed in the
Prison IV trial. For this reason, patients were further divided according
to the diameter size of the stent received into the following groups:
Group A (n = 178), patients receiving only stents with diameter ≤3mm;
Group B (n = 59), patients receiving only stents with diameter >3mm;
Group C (n = 93), patients receiving both stents with diameter >3 and
≤3mm.
Endpoints of this analysis included angiographic outcomes as in-
stent LLS, MLD, in-stent percentage of diameter stenosis, binary
restenosis, and re-occlusions at 8 months. Moreover, data regarding
lumen and stent areas as assessed with optical coherence tomography
(OCT) were included to support the angiographic findings.
QCA was assessed offline in an independent angiographic core
laboratory (St. Antonius Hospital Angiographic Core Laboratory,
Nieuwegein, theNetherlands) with automatic edge detection software
CMS version 5.3 (Medis Medical Imaging Systems, Leiden, the
Netherlands), by experienced personnel blinded to clinical information
and allocated stent. QCAmeasures included the proximal-edge, distal-
edge and in-stent diameters of the reference vessel (RVD), theminimal
luminal diameters (MLD), percentages of diameter stenosis (difference
between RVD and MLD/RVD × 100), and LLL (difference between
MLDafter the procedure andMLD at follow-up). Binary restenosis was
defined as a diameter stenosis >50% inside the stented segment at
angiographic follow-up.
The full OCT analysis, methodology and results have been
described previously.15 Briefly, 30 patients were assessed with OCT
during the 9-month follow-up procedure in both groups. All images
were recorded with a frequency domain OCT imaging system (C7XR™
or OPTIS™ OCT imaging system; St. Jude Medical, St. Paul, MN). OCT
analyses were performed offline by the local core laboratory
(University Hospital Leuven, Leuven, Belgium) in a blinded fashion.
Quantitative strut level analysis was performed every third frame
(0.6mm interval) along the entire target segment. A dedicated
automated software system developed at the LeuvenMedical Imaging
Centre was used for quantitative OCT analysis.16 The OCT measure-
ments included mean and minimum lumen area, together with stent
mean, minimum and maximum area.
Baseline and outcome data were analysed using descriptive
statistics. Numerical values were expressed as mean ± standard
deviation (SD) or median (interquartile range, IQR) as appropriate.
Categorical variables were expressed as percentages. Comparisons
between groups were performed using Pearson chi-square test for
categorical variables and student t-test for continuous variables. A two
tailed probability value of P < 0.05 was considered statistically
significant. All statistical analyses were performed using SPPS version
22.0 (SPSS, Inc., Chicago, IL).
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TABLE 2 Angiographic and procedural features in the three groups of the study population
Small stents Large stents Both
SES (n = 92) EES (n = 86) P‐value SES (n = 30) EES (n = 29) P‐value SES (n = 43) EES (n = 50) P‐value
Occluded vessel 0.24 0.86 0.79
Right coronary artery 40 (43.5%) 27 (31.4%) 21 (70%) 22 (75.9%) 33 (76.7%) 38 (76%)
Left anterior descendant 32 (34.8%) 35 (40.7%) 8 (26.7%) 6 (20.7%) 8 (18.6%) 8 (16%)
Left circumflex 20 (21.7%) 24 (27.9%) 1 (3.3%) 1 (3.4%) 2 (4.7%) 3 (6%)
Collateral filling 88 (95.7%) 84 (97.7%) 0.68 28 (93.3%) 28 (96.6%) 0.61 41 (95.1%) 47 (94%) 0.89
Bridge collaterals 43 (46.7%) 36 (41.9%) 0.55 13 (43.3%) 14 (48.3%) 0.79 17 (39.5%) 20 (40%) 0.55
Retrograde collaterals 82 (89.1%) 75 (87.2%) 0.81 28 (93.3%) 29 (100%) 0.49 42 (97.7%) 48 (96%) 0.24
Catheter size 0.53 0.34 0.27
5 2 (2.2%) 5 (5.8%) 0 0 0 0
6 83 (90.2%) 75 (87.2%) 29 (96.7%) 26 (89.7%) 39 (92.9%) 44 (88%)
7 5 (5.4%) 3 (3.5%) 1 (3.3%) 1 (3.4%) 1 (2.4%) 5 (10%)
8 2 (2.2%) 3 (3.5%) 0 2 (6.9%) 2 (4.8%) 1 (2%)
Vascular access 0.74 0.21 0.37
Single access
Femoral 41 (44.6%) 44 (51.2%) 15 (50%) 11 (37.9%) 7 (16.3%) 10 (20%)
Radial 31 (33.7%) 26 (30.2%) 7 (23.3%) 12 (41.4%) 13 (30.2%) 13 (26%)
Double access
Radial/femoral 10 (10.9%) 10 (11.6%) 7 (23.3%) 3 (10.3%) 20 (46.5%) 18 (36%)
Femoral/femoral 9 (9.8%) 6 (7%) 1 (3.3%) 3 (10.3%) 3 (7%) 9 (18%)
Radial/radial 1 (1.1%) 0 0 0 1 (0.6%) 0
Recanalization technique 0.73 0.53 0.88
Antegrade wire escalation
Single wire 79 (86.8%) 77 (90.6%) 26 (86.7%) 26 (89.7%) 27 (64.3%) 31 (62%)
Parallel wire 3 (3.3%) 4 (4.7%) 0 0 3 (7.1%) 5 (10%)
Antegrade dissection re‐entry
Mini STAR/LAST 1 (1.1%) 0 0 0 1 (2.4%) 0
Crossboss/stingray 1 (1.1%) 0 0 0 2 (4.8%) 1 (2%)
Retrograde
Retrograde wire escalation 4 (4.4%) 2 (2.4%) 3 (10%) 2 (6.9%) 4 (9.5%) 5 (10%)
Kissing wire 2 (2.2%) 2 (2.4%) 1 (3.3%) 0 1 (2.4%) 1 (2%)
Reverse CART 1 (1.1%) 0 0 1 (3.4%) 4 (9.5%) 7 (14%)
Primary approach 0.57 0.99 0.99
Antegrade 84 (91.3%) 81 (94.2%) 26 (86.7%) 26 (89.7%) 31 (72.1%) 37 (74%)
Retrograde 8 (8.7%) 5 (5.8%) 4 (13.3%) 3 (10.3%) 12 (27.9%) 13 (26%)
Japanese‐chronic total occlusion score
Meana 1.6 ± 1 1.7 ± 1 0.37 1.9 ± 1.3 2.3 ± 1.1 0.27 2 ± 1.1 2.4 ± 1.1 0.09
Risk group 0.13 0.77 0.37
0 (Easy) 13 (14.1%) 5 (5.8%) 4 (13.3%) 1 (3.4%) 3 (7%) 2 (4%)
1 (Intermediate) 31 (33.7%) 36 (41.9%) 8 (26.7%) 6 (20.7%) 13 (30.2%) 7 (14%)
2 (Difficult) 31 (33.7%) 24 (27.9%) 8 (26.7%) 10 (34.5%) 11(25.6%) 18(36%)
≥3 (Very difficult) 17 (18.4%) 21 (24.5%) 10 (33.3%) 12 (41.3%) 16 (37.2%) 23 (46%)
Variables
Blunt stump 32 (34.8%) 39 (45.3%) 0.17 14 (46.7%) 17 (58.6%) 0.44 17 (39.5%) 32 (64%) 0.02
Calcification 56 (60.9%) 53 (61.3%) 0.99 18 (60%) 19 (65.5%) 0.79 29 (67.4%) 38 (76%) 0.49
(Continues)
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3 | RESULTS
Demographic data between the two deviceswere evenly distributed in
the three sub-groups (see Table 1). Of note, left ventricle ejection
fraction (LVEF) showed a trend toward worse values in the EES cohort
of Group A (7.6% vs 18.7% of patients with LVEF <50%, P = 0.07).
Similarly, angiographic baseline characteristics were comparable in the
two treatment arms of all three sub-groups (see Table 2). The only
significant difference was noted in Group C, where coronary lesions in
the EES group showed a proximal blunt stumpmore frequently than in
the SES group (64% vs 39.5%, respectively, P = 0.02), with a mean J-
CTO score broadly comparable (2.4 ± 1.1 vs 2 ± 1.1, respectively,
P = 0.09). The prevalence of calcified pattern in the CTO lesion was
high (from 60% to 76%) and comparable in all the groups. The most
successful recanalization technique was antegrade wire escalation
(AWE) in all sub-groups without significant differences between the
treatment arms; however in Group C a trend toward more common
adoption of retrograde techniques can be observed, resulting in
broadly longer stented segments if compared with the two remaining
groups (see Table 2). Consistently with the sub-groups division, the
mean stent diameter was 2.85 ± 0.22mm in Group A, 3.67 ± 0.24mm
in Group B, and 3.55 ± 0.16mm in Group C, without significant
differences between the two treatment cohorts.
CompleteQCA results for all the study groups are listed in Table 3.
In GroupA, post-procedural in-stent RVD,MLD, andDSwere similar in
the SES and EES group. At 9 month follow-up, the proximal and distal
RVDs increased in both treatment groups (P = ns), while in-stent RVD
remained stable. In-stent MLD showed a trend toward lower values in
the SES group when compared with the EES group (2.06 ± 0.61mm vs
2.21 ± 0.48mm, P = 0.08), with a strong tendency to higher in-stent DS
(26.04 ± 18.59% and 21.24 ± 12.84%, respectively, P = 0.06), and a
similar in-stent LLL. The binary restenosis rate, however, was
significantly higher in the SES group: 8 (10.3%) versus 1 (1.3%),
P = 0.03.
In Group B reference diameters after PCI were similar and
higher than in Group-A, reflecting the mean stent diameter
implanted in this population, with also similar in-stent MLD and
DS. At 9 month follow-up, all RVDs slightly increased in both
treatment groups (P = ns), with comparable in-stent MLD and DS. In
addition, in-stent LLL resulted low and comparable in the two
cohorts (0.03 ± 0.78 mm vs 0.02 ± 0.41, respectively, P = 0.97), as
was the incidence of binary restenosis.
In Group C, reference diameters after PCI were higher in the SES
arm (proximal RVD 3.65 ± 0.49mm and 3.46 ± 0.37mm, respectively,
P = 0.04), showing a significantly higher proximal percentage DS in the
same population (8.25 ± 10.70% vs 2.12 ± 8.62%, respectively,
P = 0.003). On the other hand, similar in-stent RVD and in-stent DS
were observed. At 9 month follow-up, proximal RVD was significantly
higher in the SES group (3.78 ± 0.55mm vs 3.56 ± 0.40mm, P = 0.05),
while in-stentMLD, in-stent LLL, and the incidence of binary restenosis
were comparable in the two cohorts (Figure 1).
A complete list of OCT results for the three study groups is shown
in Table 4. In Group A,mean lumen area andminimum lumen areawere
very similar in both study arms. Broadly lower values, although
statistically non-significant, were observed forminimum stent area and
mean stent area in the SES group (4.4 ± 1.02mm2 vs 5.0 ± 1.28mm2
and 5.28 ± 1.05mm2 vs 6.1 ± 1.36mm2, respectively).
In Group B, measurements of lumen minimal and mean area were
similar in SES and EES. Stent mean, minimal and maximum area were
also not significantly different between the two study arms, but of
TABLE 2 (Continued)
Small stents Large stents Both
SES (n = 92) EES (n = 86) P‐value SES (n = 30) EES (n = 29) P‐value SES (n = 43) EES (n = 50) P‐value
Bending 8 (8.7%) 8 (9.3%) 0.99 9 (30%) 14 (48.3%) 0.18 13 (32.6%) 12 (24%) 0.48
Lenght 39 (42.4%) 41 (47.7%) 0.55 15 (50%) 15 (51.7%) 0.99 23 (53.5%) 24 (48%) 0.68
Re‐try 1 (1.1%) 1 (1.2%) 0.99 0 0 NA 0 1 (2%) 0.99
Stent diametera 2.87 ± 0.21 2.83 ± 0.24 0.19 3.69 ± 0.24 3.65 ± 0.23 0.56 3.54 ± 0.18 3.55 ± 0.15 0.92
Stent balloon pressurea 14.6 ± 3 14.9 ± 3.1 0.49 14.7 ± 3.6 14.5 ± 3.1 0.86 15.6 ± 2.9 15.1 ± 3.1 0.47
Post‐dilation 27 (29.3%) 34 (39.5%) 0.16 12 (40%) 9 (31%) 0.59 18 (41.9%) 15 (30%) 0.28
Non‐compliant balloon 23 (85.2%) 26 (74.3%) 0.47 10 (83.3%) 8 (88.9%) 0.99 15 (83.3%) 12 (80%) 0.99
Post‐dilation diametera 3.15 ± 0.37 3.14 ± 0.36 0.92 3.98 ± 0.6 3.89 ± 0.41 0.69 3.72 ± 0.3 3.6 ± 03 0.28
Post‐dilation pressurea 18 ± 4.2 18 ± 4.1 0.97 19.1 ± 4.3 21.7 ± 4.2 0.2 18.5 ± 4.9 20.1 ± 2.8 0.28
Total stent lenghta 45 ± 21 40 ± 20 0.12 41 ± 22 39 ± 16 0.63 73 ± 24 81 ± 24 0.16
Number of stentsa 1.76 ± 0.8 1.67 ± 0.8 0.47 1.66 ± 0.8 1.41 ± 0.5 0.17 2.88 ± 1.07 2.82 ± 0.85 0.75
TIMI‐flow final 0.37 1 0.99
0 0 1 (1.2%) 0 0 0 0
1 0 0 0 0 0 0
2 1 (1.1%) 0 0 0 1 (2.3%) 1 (2%)
3 91 (98.9%) 85 (98.8%) 29 (100%) 30 (100%) 42 (97.7) 49 (98%)
aMean ± SD.
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note, SES values tended to be higher than those in the EES arm. Similar
findings were reported in Group C.
4 | DISCUSSION
The ultrathin struts (60 μm) of the hybrid SES were designed to limit
the arterial injury and amount of metallic-body placed with stent
implantation, thus hindering two possible mechanisms responsible for
restenosis. The present sub-analysis from the PRISON IV trial suggests
that the relatively inferior performance of this device is confirmed
when smaller stents (≤3mm in diameter) are adopted, which indeed
consist of those with the ultra-thin struts. In fact, in this population
(Group A), despite similar baseline patients characteristics and
comparable angiographic (eg, J-CTO score) and procedural (stent
diameter and inflation pressure, post-dilation, use of NC-balloons)
features, the follow-upQCA disclosed a strong trend toward higher in-
stent DS (26.04 ± 18.59% vs 21.24 ± 12.84%, P = 0.06) and a statisti-
cally significant, nearly eightfold higher, incidence of binary-restenosis
(P = 0.03). A possible explanation for these observations could be the
reduced radial strength offered by the ultra-thin struts devices, as
potentially supported by the OCT analysis, which showed a mild trend
toward lower stent area values in this group. An alternative
explanation could be identified in a lower neo-intimal inhibition
operated by the hybrid SES, with more pronounced effects in vessel
with smaller diameter. Indeed, these findings were not confirmed in
the population receiving larger stents (>3mm in diameter, Group B),
where the SES struts thickness is equal to 80 μm (as that of all EES
stents), despite the lownumber of patients included in this group poses
relevant limitations in drawing firm conclusions. In fact, similar
TABLE 3 Quantitative Coronary Analysis (QCA) results in the three groups of the study population
Small stents (n = 178) Large stents (n = 59) Both (n = 93)
SES (n = 92) EES (n = = 86) P‐value SES (n = 30) EES (n = 29) P‐value SES (n = 43) EES (n = 50) P‐value
Pre‐procedure
Occlusion lenght 19.3 ± 12.6 18.7 ± 9.8 0.76 20.8 ± 9.1 19.9 ± 8.9 0.74 22.4 ± 13.8 25.1 ± 21.6 0.49
Proximal RVD 2.44 ± 0.87 2.57 ± 0.93 0.32 2.71 ± 0.88 2.96 ± 1 0.33 2.68 ± 1.24 2.52 ± 1.22 0.54
Post‐procedure
Proximal RVD 2.96 ± 0.35 2.97 ± 0.37 0.81 3.71 ± 0.49 3.70 ± 0.47 0.99 3.65 ± 0.49 3.46 ± 0.37 0.04
Proximal Edge RVD 2.92 ± 0.35 2.93 ± 0.37 0.9 3.66 ± 0.47 3.63 ± 0.43 0.84 3.61 ± 0.48 3.44 ± 0.37 0.06
Proximal Edge MLD 2.77 ± 0.42 2.76 ± 0.37 0.9 3.55 ± 0.53 3.52 ± 0.45 0.78 3.29 ± 0.44 3.36 ± 0.45 0.45
Proximal DS% 4.98 ± 8.92 5.23 ± 8.27 0.85 2.69 ± 9.6 3.17 ± 6.02 0.82 8.25 ± 10.70 2.12 ± 8.62 0.003
Distal RVD 2.28 ± 0.38 2.26 ± 0.42 0.77 3.02 ± 0.31 2.97 ± 0.36 0.56 2.48 ± 0.41 2.45 ± 0.36 0.74
Distal Edge RVD 2.33 ± 0.36 2.32 ± 0.39 0.88 3.07 ± 0.3 3.03 ± 0.36 0.66 2.54 ± 0.4 2.51 ± 0.34 0.69
Distal Edge MLD 2.28 ± 0.39 2.30 ± 0.38 0.78 3.05 ± 0.33 3.01 ± 0.41 0.72 2.52 ± 0.4 2.48 ± 0.33 0.65
Distal DS % 2.01 ± 9 0.58 ± 10.01 0.32 0.71 ± 5.07 0.47 ± 8.78 0.89 0.35 ± 9.66 0.66 ± 8.3 0.87
In‐stent RVD 2.73 ± 0.35 2.71 ± 0.4 0.81 3.4 ± 0.38 3.36 ± 0.38 0.71 3.16 ± 0.58 2.97 ± 0.38 0.07
In‐stent MLD 2.24 ± 0.33 2.23 ± 0.36 0.74 2.81 ± 0.37 2.81 ± 0.24 0.98 2.43 ± 0.42 2.36 ± 0.41 0.43
In‐stent DS% 17.54 ± 7.49 17.75 ± 7.15 0.85 17.23 ± 7.19 16 ± 5.91 0.48 22.79 ± 6.97 20.92 ± 7.11 0.21
9‐month follow‐up
Proximal RVD 3.04 ± 0.35 3.1 ± 0.46 0.34 3.88 ± 0.54 3.73 ± 0.59 0.35 3.78 ± 0.55 3.56 ± 0.40 0.05
Proximal Edge RVD 2.93 ± 0.59 3.01 ± 0.57 0.39 3.67 ± 0.93 3.7 ± 0.57 0.91 3.75 ± 0.55 3.47 ± 0.68 0.06
Proximal Edge MLD 2.78 ± 0.6 2.86 ± 0.59 0.4 3.38 ± 0.97 3.52 ± 0.66 0.55 3.6 ± 0.55 3.37 ± 0.75 0.13
Proximal DS% 5.05 ± 7.8 4.78 ± 11.01 0.86 7.86 ± 9.47 4.78 ± 9.61 0.25 3.63 ± 8.15 2.84 ± 10.12 0.71
Distal RVD 2.36 ± 0.39 2.44 ± 0.42 0.26 3.26 ± 0.46 3.33 ± 0.82 0.73 2.71 ± 0.35 2.64 ± 0.42 0.4
Distal Edge RVD 2.37 ± 0.51 2.45 ± 0.49 0.29 3.19 ± 0.79 3.36 ± 0.78 0.47 2.76 ± 0.34 2.63 ± 0.57 0.23
Distal Edge MLD 2.33 ± 0.54 2.41 ± 0.52 0.32 3.11 ± 0.81 3.2 ± 0.58 0.65 2.73 ± 0.38 2.57 ± 0.59 0.17
Distal DS % 1.43 ± 8.61 1.38 ± 9.04 0.97 2.43 ± 6.51 2.98 ± 12.3 0.84 1.23 ± 8.04 1.99 ± 11.78 0.75
In‐stent RVD 2.69 ± 0.58 2.76 ± 0.51 0.4 3.51 ± 0.86 3.6 ± 0.69 0.67 3.2 ± 0.44 3.03 ± 0.66 0.22
In‐stent MLD 2.06 ± 0.61 2.21 ± 0.48 0.08 2.76 ± 0.79 2.79 ± 0.46 0.86 2.44 ± 0.4 2.23 ± 0.62 0.1
In‐stent DS% 26.04 ± 18.59 21.24 ± 12.84 0.06 24.30 ± 19.54 21.55 ± 11.32 0.54 23.43 ± 9.83 28.54 ± 15.05 0.09
In‐stent LLL 0.19 ± 0.60 0.05 ± 0.42 0.1 0.03 ± 0.78 0.02 ± 0.41 0.97 0.01 ± 0.32 0.15 ± 0.55 0.19
In‐stent binary restenosis 8 (10.3%) 1 (1.3%) 0.03 2 (8%) 0 0.23 1 (2.9%) 2 (4.8%) 0.99
Re‐occlusion 2 (2.2%) 1 (1.2%) 0.99 1 (3.3%) 0 0.99 0 1 (2%) 0.99
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evolutions in RVDs were observed in the two groups between post-
procedural analysis and follow-up, without any increase in in-stent LLL
or binary restenosis rate, which, on the contrary, resulted similar to
those of the EES cohort in Group A. Consistent findingswere observed
in the OCT analysis, with stent area values substantially identical in the
two groups. Finally, findings from the hybrid Group C, where stent of
both sizes (≤3 and >3mm) were used, are unavoidably less clearly
oriented. In this group, the total stent length resulted higher than in the
other two groups, with need for more stents implanted (see Table 2).
The common adoption of different number of both stent sizes (small
and large), with the respective different lengths, makes the two
cohorts of this group highly heterogeneous and thus not appropriate
for clear interpretation.
In the settings of complex coronary lesions, such as CTOs, the
benefits of the ultra-thin struts in terms of reduced vascular injury and
thrombogenicity are possibly counterpartyed by an inferior vessel-wall
supportive strength. The high prevalence of calcified lesions (ranging
from 60% to 76% of patients in the different cohorts) and a generally
greater lesion length (more than 20mm in almost 50% of cases) could
be possible elements hindering the performance of the ultra-thin struts
SES in the present settings. However, larger and dedicated trials are
needed to confirm our findings.
5 | LIMITATIONS
Data presented in this sub-analysis derived from the randomized
Prison IV trial, which makes our findings solid. However, some
limitations must be acknowledged. First, the study was not designed
to assess angiographic differences in the sub-group of patients
receiving stent with diameter ≤3mm. Second, QCA results, although
clearly oriented, especially in Group A, are limited by the absolute
low number of patients analysed in the cohort. Third, the clinical
implications of these findings were not investigated in this sub-
analysis, thus caution should be used before translating our results
into clinical indications. In addition, the OCT analysis was carried out
in an exploratory way, without mandatory assessments in the two
groups of treatment, with consequent limited number of
FIGURE 1 Incidence of binary restenosis in the two cohorts of treatment stratified in the three groups of analysis
TABLE 4 Optical coherence tomography findings in the three groups of the study population
Small stents (n = 39) Large stents (n = 11) Both (n = 10)
SES
(n = 17)
EES
(n = 22) P-value
SES
(n = 7)
EES
(n = 4) P-value SES (n = 6)
EES
(n = 4) P-value
Lumen Measurements
Mean lumen area (mm2)a 5.8 ± 1.28 5.8 ± 1.39 0.92 9.0 ± 2.91 8.7 ± 0.97 0.77 8.5 ± 2.36 7.3 ± 1.06 0.45
Minimum lumen area (mm2)a 3.7 ± 1.45 4.0 ± 1.37 0.72 7.1 ± 2.3 6.8 ± 0.9 0.64 4.9 ± 0.99 4.3 ± 0.56 0.45
Stent Measurements
Mean stent area (mm2)a 5.8 ± 1.05 6.1 ± 1.36 0.26 8.9 ± 2.44 8.8 ± 0.91 0.92 8.1 ± 1.65 8.0 ± 1.67 1
Minimum stent area (mm2)a 4.4 ± 1.02 5.0 ± 1.28 0.16 7.6 ± 2.06 7.4 ± 1.0.6 0.92 5.5 ± 0.87 5.4 ± 0.95 0.91
Maximum stent area (mm2)a 7.2 ± 1.52 7.5 ± 1.7 0.33 11.1 ± 2.42 10.5 ± 1.17 1 11.1 ± 3.32 11.2 ± 1.45 0.91
aMean ± standard deviation.
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examinations available. Finally, OCT analysis was performed only
during the 9-month follow-up procedure, thus comparison with basal
post-procedural results was not possible.
CONFLICTS OF INTEREST
All authors meet the authorship criteria, take full responsibility for all
aspects of the reliability and freedom from bias of the data presented,
and their discussed interpretation. The authors report no financial
relationships or conflict of interest regarding the content herein.
ORCID
Carlo Zivelonghi http://orcid.org/0000-0001-9825-6589
REFERENCES
1. Maeremans J, Walsh S, Knaapen P, et al. The hybrid algorithm for
treating chronic total occlusions in Europe: the RECHARGE registry.
J Am Coll Cardiol. 2016;68:1958–1970.
2. Teeuwen K, van der Schaaf RJ, Adriaenssens T, et al. Randomized
multicenter trial investigating angiographic outcomes of hybrid sirolimus-
eluting stents with biodegradable polymer compared with everolimus-
eluting stents with durable polymer in chronic total occlusions: the
PRISON IV trial. JACC Cardiovasc Interv. 2017;10:133–143.
3. Mehran R, Claessen BE, Godino C, et al. Multinational chronic total
occlusion registry. Long-term outcome of percutaneous coronary
intervention for chronic total occlusions. JACC Cardiovasc Interv.
2011;4:952–961.
4. Jones DA,Weerackody R, Rathod K, et al. Successful recanalization of
chronic total occlusions is associated with improved long-term
survival. JACC Cardiovasc Interv. 2012;5:380–388.
5. Valenti R, Migliorini A, Signorini U, et al. Impact of complete
revascularization with percutaneous coronary intervention on survival
in patients with at least one chronic total occlusion. Eur Heart J.
2008;29:2336–2342.
6. Taniwaki M, Stefanini GG, Silber S, et al. 4-year clinical outcomes
and predictors of repeat revascularization in patients treated
with new-generation drug-eluting stents: a report from the
RESOLUTE all-comers trial (a randomized comparison of a
zotarolimus-eluting stent with an everolimus-eluting stent for
percutaneous coronary intervention). J Am Coll Cardiol. 2014;63:
1617–1625.
7. Yeh RW, Silber S, Chen L, et al. 5-year safety and efficacy of resolute
zotarolimus-eluting stent: the RESOLUTE global clinical trial program.
JACC Cardiovasc Interv. 2017;10:247–254.
8. Di Mario C, Serruys PW, Silber S, et al. Long-term outcomes after
Resolute zotarolimus-eluting stent implantation in patients with ST-
segment elevation acute myocardial infarction: insights from the
RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial
Program. EuroIntervention. 2016;12:1207–1214.
9. Hasegawa K, Tsuchikane E, Okamura A, et al. Incidence and impact on
midterm outcome of intimal versus subintimal tracking with both
antegrade and retrograde approaches in patients with successful
recanalisation of chronic total occlusions: J-PROCTOR 2 study.
EuroIntervention. 2017;12:e1868–e1873.
10. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and
angiographic results: strut thickness effect on restenosis outcome
(ISAR-STEREO) trial. Circulation. 2001;103:2816–2821.
11. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and
angiographic results: strut thickness effect on restenosis outcome
(ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283–1288.
12. Smits PC, Vlachojannis GJ, McFadden EP, et al. Final 5-year follow-up
of a randomized controlled trial of everolimus- and paclitaxel-eluting
stents for coronary revascularization in daily practice: the COMPARE
trial (a trial of everolimus-eluting stents and paclitaxel stents for
coronary revascularization in daily practice). JACC Cardiovasc Interv.
2015;8:1157–1165.
13. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus
paclitaxel-eluting stents in coronary artery disease. N Engl J Med.
2010;362:1663–1674.
14. Teeuwen K, Adriaenssens T, Van den Branden BJ, et al. A randomized
multicenter comparison of hybrid sirolimus-eluting stents with
bioresorbable polymer versus everolimus-eluting stents with durable
polymer in total coronary occlusion: rationale and design of the
primary stenting of occluded native coronary arteries IV study. Trials.
2012;13:240.
15. Teeuwen K, Spoormans EM, Bennett J, et al. Optical coherence
tomography findings: insights from the “randomised multicentre trial
investigating angiographic outcomes of hybrid sirolimus-eluting
stents with biodegradable polymer compared with everolimus-
eluting stents with durable polymer in chronic total occlusions”
(PRISON IV) trial. EuroIntervention. 2017;13:e522–e530.
16. Ughi GJ, Adriaenssens T, Onsea K, et al. Automatic segmentation of in-
vivo intra-coronary optical coherence tomography images to assess
stent strut apposition and coverage. Int J Cardiovasc Imaging 2012;28:
229–241.
How to cite this article: Zivelonghi C, Teeuwen K, Agostoni
P, et al. Impact of ultra-thin struts on restenosis after chronic
total occlusion recanalization: Insights from the randomized
PRISON IV trial. J Interven Cardiol. 2018;31:580–587.
https://doi.org/10.1111/joic.12516
ZIVELONGHI ET AL. | 587
